Nuvectis Pharma, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

132.25 k

Shareholding (Jun 2025)

FII

1.79%

Held by 22 FIIs

DII

91.86%

Held by 7 DIIs

Promoter

0.00%

How big is Nuvectis Pharma, Inc.?

22-Jun-2025

As of Jun 18, Nuvectis Pharma, Inc. has a market capitalization of 169.45 million, with net sales of 0.00 million and a net profit of -20.16 million over the last four quarters. The company reported shareholder's funds of 9.71 million and total assets of 18.61 million as of Dec 24.

What does Nuvectis Pharma, Inc. do?

22-Jun-2025

Nuvectis Pharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $169.45 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -96.22%.

Is Nuvectis Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of August 21, 2025, Nuvectis Pharma, Inc. shows a bearish technical trend with weak momentum indicators, having underperformed the S&P 500 recently while lagging significantly over the past year and three years.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 163 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.59

Return on Equity

-130.79%

Price to Book

9.66

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

6.22%

6 Months

-24.55%

1 Year

35.71%

2 Years

-19.8%

3 Years

-10.19%

4 Years

0.0%

5 Years

0.0%

Nuvectis Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Nuvectis Pharma, Inc. technically bullish or bearish?

As of 21 August 2025, the technical trend for Nuvectis Pharma, Inc. has changed from mildly bearish to bearish. The weekly MACD is bearish, and the daily moving averages also indicate a bearish stance. Bollinger Bands reflect a mildly bearish condition on the weekly chart and a bearish condition on the monthly chart. The KST is bearish for both weekly and monthly periods. There are no signals from the RSI, and Dow Theory shows no trend in either time frame. In terms of performance, Nuvectis has underperformed the S&P 500 over the past week (-1.69% vs. +1.05%) and the past month (-0.78% vs. +2.33%), while it has outperformed the benchmark year-to-date (18.3% vs. 12.22%). However, it has significantly lagged over the past year (-4.48% vs. +17.14%) and the past three years (-21.95% vs. +70.41%). Overall, the current technical stance is bearish with weak momentum indicators....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-48.83%

EBIT to Interest (avg)

-15.99

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.43

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

10.13%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

8.82

EV to EBIT

-7.38

EV to EBITDA

-7.38

EV to Capital Employed

-17.40

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-96.22%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bullish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 10 Schemes (6.34%)

Foreign Institutions

Held by 22 Foreign Institutions (1.79%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -43.18% vs 22.81% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.60",
          "val2": "-4.60",
          "chgp": "-43.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.30",
          "val2": "-4.40",
          "chgp": "-43.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 14.80% vs -16.75% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.80",
          "val2": "-22.90",
          "chgp": "13.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-19.00",
          "val2": "-22.30",
          "chgp": "14.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.60

-4.60

-43.48%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-6.30

-4.40

-43.18%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -43.18% vs 22.81% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-19.80

-22.90

13.54%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-19.00

-22.30

14.80%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 14.80% vs -16.75% in Dec 2023

All Annual Results

Company CV

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Nuvectis Pharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Nuvectis Pharma, Inc.?

Watch in Real-Time

What does Nuvectis Pharma, Inc. do?

Is Nuvectis Pharma, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Nuvectis Pharma, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Jun 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Nuvectis Pharma, Inc.

Company Coordinates